ArticleDiscover oncology2025
Single nucleotide polymorphism and expression of P16 gene as a potential biomarker for oral and pre-oral cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study investigated the association between p16 gene and its 450 C > G (rs11515) polymorphism with risk of oral cancer and precancerous oral lesions/oral potentially malignant disorder (OPMD).
methodThe study included 230 individuals with OPMD conditions (70 with leukoplakia, 90 with oral submucous fibrosis, and 70 with lichen planus), 72 oral cancer patients, and 300 cancer-free healthy controls. Genotyping of the p16 450 C > G polymorphism was conducted using PCR-RFLP methods, and genotype and allele frequencies were analyzed using chi-square test. Additionally, p16 gene expression levels were measured using RT-PCR among oral cancer patients, those with OPMD, and healthy controls. RNA fold was used to calculate the MFE of p16 mRNA.
resultsThe findings revealed that G allele of p16 450 C > G polymorphism significantly increased risk of oral diseases (oral cancer and OPMD) compared to C allele (OR 1.67, p = 0.0001). GG genotype was associated with higher risk of oral submucous fibrosis (OR 4.63, p = 0.0001), lichenplanus (OR 3.93, p = 0.0002), and leukoplakia (OR 2.38, p = 0.02) compared to CC genotype. Smokers and tobacco chewers carrying the G allele were at a significantly increased risk of developing OPMD (OR = 3.78 and 2.89). Notably, p16 transcript expression was significantly elevated (13.56-fold) in oral cancer patients compared to healthy controls. According to insilco analysis G allele gives more stable transcript of p16 (MEF - 64.90 kcal/mol) compared to C allele (MFE - 61.70 kcal/mol).
conclusionThese findings suggest that p16 gene and its 450 C > G polymorphism may be associated with risk of oral diseases, indicating their potential utility as biomarkers for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.